
Michael Ehlers
Interim President and CEO, Ascidian Therapeutics
Interim President and CEO, Ascidian Therapeutics
May 30, 2024
If we can edit RNA at the kilobase scale, we can treat more diseases at the genetic level
4 min read
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
False
False